MX2023002419A - Metodos para el tratamiento del embolismo por cristales de colesterol con ciclodextrinas. - Google Patents

Metodos para el tratamiento del embolismo por cristales de colesterol con ciclodextrinas.

Info

Publication number
MX2023002419A
MX2023002419A MX2023002419A MX2023002419A MX2023002419A MX 2023002419 A MX2023002419 A MX 2023002419A MX 2023002419 A MX2023002419 A MX 2023002419A MX 2023002419 A MX2023002419 A MX 2023002419A MX 2023002419 A MX2023002419 A MX 2023002419A
Authority
MX
Mexico
Prior art keywords
methods
embolization
individual
cyclodextrins
treatment
Prior art date
Application number
MX2023002419A
Other languages
English (en)
Spanish (es)
Inventor
Diana Kerwin
Jason Camm
Original Assignee
Beren Therapeutics P B C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beren Therapeutics P B C filed Critical Beren Therapeutics P B C
Publication of MX2023002419A publication Critical patent/MX2023002419A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
MX2023002419A 2020-08-27 2021-08-27 Metodos para el tratamiento del embolismo por cristales de colesterol con ciclodextrinas. MX2023002419A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063071222P 2020-08-27 2020-08-27
PCT/US2021/048072 WO2022047241A1 (en) 2020-08-27 2021-08-27 Methods for the treatment of cholesterol crystal embolization with cyclodextrins

Publications (1)

Publication Number Publication Date
MX2023002419A true MX2023002419A (es) 2023-07-11

Family

ID=80353289

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002419A MX2023002419A (es) 2020-08-27 2021-08-27 Metodos para el tratamiento del embolismo por cristales de colesterol con ciclodextrinas.

Country Status (11)

Country Link
US (1) US20230330133A1 (cg-RX-API-DMAC10.html)
EP (1) EP4203972A4 (cg-RX-API-DMAC10.html)
JP (1) JP7835735B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230096975A (cg-RX-API-DMAC10.html)
CN (1) CN116322643A (cg-RX-API-DMAC10.html)
AU (1) AU2021333902A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023003455A2 (cg-RX-API-DMAC10.html)
CA (1) CA3190563A1 (cg-RX-API-DMAC10.html)
IL (1) IL300806A (cg-RX-API-DMAC10.html)
MX (1) MX2023002419A (cg-RX-API-DMAC10.html)
WO (1) WO2022047241A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016276774A1 (en) 2015-06-10 2018-01-18 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
EP4294403A4 (en) * 2021-02-18 2024-12-11 Beren Therapeutics P.B.C. METHODS OF TREATMENT OF HETEROZYGOUS AND HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA WITH CYCLODEXTRINS
JP2025506676A (ja) 2022-02-18 2025-03-13 ベレン セラピューティクス ピー．ビー．シー． ヒドロキシプロピル－ベータ－シクロデキストリンの組成物及びその精製方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
WO2013155485A2 (en) * 2012-04-13 2013-10-17 Alessia Fornoni Method of using cyclodextrin

Also Published As

Publication number Publication date
JP7835735B2 (ja) 2026-03-25
EP4203972A1 (en) 2023-07-05
BR112023003455A2 (pt) 2023-05-02
KR20230096975A (ko) 2023-06-30
AU2021333902A1 (en) 2023-03-16
EP4203972A4 (en) 2024-07-17
US20230330133A1 (en) 2023-10-19
JP2023543133A (ja) 2023-10-13
WO2022047241A1 (en) 2022-03-03
CN116322643A (zh) 2023-06-23
CA3190563A1 (en) 2022-03-03
IL300806A (en) 2023-04-01

Similar Documents

Publication Publication Date Title
Fillingham et al. Tranexamic acid in total joint arthroplasty: the endorsed clinical practice guides of the American association of hip and knee surgeons, American society of regional anesthesia and pain medicine, American academy of orthopaedic surgeons, hip society, and knee society
Mei et al. The efficacy of tranexamic acid for orthognathic surgery: a meta-analysis of randomized controlled trials
Behrens et al. A review of modern management of lateral epicondylitis
BR112023003455A2 (pt) Métodos para o tratamento de embolização por cristais de colesterol com ciclodextrinas
Xie et al. Administration of tranexamic acid reduces postoperative blood loss in calcaneal fractures: a randomized controlled trial
GB0410266D0 (en) Treatment of apoptosis
Yu et al. Can tranexamic acid reduce blood loss in cervical laminectomy with lateral mass screw fixation and bone grafting: a retrospective observational study
Sveinsson et al. Intra-arterial mechanical thrombectomy: an effective treatment for ischemic stroke caused by endocarditis
Kinov et al. Antithrombotic prophylaxis in major orthopaedic surgery: an historical overview and update of current recommendations
Ferreira et al. Two stage reconstruction of septic non-union of the humerus with the use of circular external fixation
Avila et al. Lip cavernous hemangioma in a young child
Sawant et al. The impact of tranexamic acid on blood loss management in primary total knee arthroplasty: a comprehensive review
Xu et al. The combined application of pulsed electromagnetic fields and platelet-rich plasma in the treatment of early-stage knee osteoarthritis: A randomized clinical trial
Mathews et al. Surgery for hemophilia in developing countries
Jazayeri et al. Reevaluating the role of heparin during mechanical thrombectomy for acute ischemic stroke: Increased risks without functional benefit
Harju et al. Comparison of the quality of life after minilaparotomy cholecystectomy versus laparoscopic cholecystectomy: a prospective randomized study.
Nadeau et al. Antifibrinolytic therapy for perioperative blood conservation in lower-extremity primary total joint arthroplasty
MX2023002420A (es) Métodos para la prevención del embolismo por cristales de colesterol con ciclodextrinas.
Harsha Complications of rhinoplasty
WO2025137652A3 (en) Compositions comprising radiprodil and the use of radiprodil in the treatment of epileptic or neurobehavioral disorders
Selvaratnam et al. Does pre-operative tranexamic acid increase the incidence of thromboembolism in primary lower limb arthroplasty
Landro et al. Platelet-rich plasma for musculoskeletal disorders: No infection reported in daily practice
Shrader et al. Pulmonary embolism following an ankle fracture in a 9-year-old boy: a case report.
Sadeghpour et al. Effect of tranexamic acid on transfusion and blood loss in acetabular fracture surgery: a randomized clinical trial
US20070128181A1 (en) Methods of Preventing Morbidity and Mortality by Perioperative Administration of a Blood Clotting Inhibitor